Bratton Capital Management’s Denali Therapeutics DNLI Stock Holding History

Bratton Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-448,035	Closed	-$16.1M	–	2
2020 Q3	$16.1M	Hold	448,035	–	–	22.33%	2
2020 Q2	$10.8M	Sell	448,035 -505,000	-53%	-$11.9M	16.23%	2
2020 Q1	$16.7M	Hold	953,035	–	–	39.85%	2
2019 Q4	$16.6M	Hold	953,035	–	–	19.87%	2
2019 Q3	$14.6M	Hold	953,035	–	–	28.53%	2
2019 Q2	$19.8M	Hold	953,035	–	–	29.05%	2
2019 Q1	$22.1M	Sell	953,035 -158,764	-14%	-$3.32M	21.78%	2
2018 Q4	$23M	Buy	+1,111,799	New	+$20.2M	24.06%	2

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bratton Capital Management's DNLI Position: Q4 2020 in Review

Bratton Capital Management sold out of Denali Therapeutics (DNLI) in Q4 2020, closing a stake of 448,035 shares — an estimated $16.1M sold.

Bratton Capital Management first reported a position in DNLI in Q4 2018 and held it in 8 quarters. The position peaked at $23M in Q4 2018. 205 funds tracked by Wall St. Rank hold DNLI as of Q4 2020.

Bratton Capital Management reported no remaining Denali Therapeutics position as of Q4 2020 after selling out during the quarter.
Bratton Capital Management sold 448,035 Denali Therapeutics shares in Q4 2020, an estimated $16.1M.
Bratton Capital Management first reported a position in Denali Therapeutics in Q4 2018 and held it in 8 quarters.
Bratton Capital Management's Denali Therapeutics position peaked at $23M in Q4 2018.
205 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2020.

Based on Bratton Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.